SEC 13F Intelligence

Rhenman & Partners Asset Management AB / ALNY

Rhenman & Partners Asset Management AB’s Alnylam Pharmaceuticals Inc Position

Does Rhenman & Partners Asset Management AB own Alnylam Pharmaceuticals Inc (ALNY)? Yes — 34.5K shares worth $11M (+1.41% of its 13F portfolio) as of Q1 2026, down from 45.7K shares the prior filed quarter.

Position Value
$11M
Q1 2026
Shares
34.5K
% of Portfolio
+1.41%
Quarters Held
30
currently held

Position History ALNY

Reported value by quarter
Q4 ’18: $8MQ4 ’18Q1 ’19: $9MQ2 ’19: $6MQ3 ’19: $6MQ4 ’19: $7MQ4 ’19Q1 ’20: $9MQ2 ’20: $9MQ3 ’20: $15MQ4 ’20: $15MQ4 ’20Q1 ’21: $19MQ2 ’21: $23MQ3 ’21: $19MQ4 ’21: $30MQ4 ’21Q1 ’22: $21MQ2 ’22: $11MQ3 ’22: $16MQ4 ’22: $17MQ4 ’22Q1 ’23: $15MQ2 ’23: $9MQ3 ’23: $8MQ4 ’23: $7MQ4 ’23Q1 ’24: $6MQ2 ’24: $21MQ3 ’24: $14MQ4 ’24: $4MQ4 ’24Q1 ’25: $13MQ2 ’25: $17MQ3 ’25: $15MQ4 ’25: $18MQ4 ’25Q1 ’26: $11Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202634.5K$11M+1.41%
Q4 202545.7K$18M+1.70%
Q3 202531.9K$15M+1.61%
Q2 202551.2K$17M+2.11%
Q1 202548.2K$13M+1.50%
Q4 202417.0K$4M+0.41%
Q3 202450.4K$14M+1.12%
Q2 202485.5K$21M+1.99%
Q1 202442.3K$6M+0.60%
Q4 202337.5K$7M+0.72%
Q3 202345.0K$8M+0.86%
Q2 202345.0K$9M+0.90%
Q1 202376.0K$15M+1.63%
Q4 202273.0K$17M+1.81%
Q3 202275.0K$16M+1.63%
Q2 202275.0K$11M+1.24%
Q1 2022130.0K$21M+2.09%
Q4 2021175.0K$30M+1.99%
Q3 2021100.0K$19M+1.33%
Q2 2021135.0K$23M+1.55%
Q1 2021135.0K$19M+1.33%
Q4 2020111.7K$15M+1.18%
Q3 2020100.0K$15M+1.29%
Q2 202062.1K$9M+0.99%
Q1 202080.0K$9M+1.22%
Q4 201960.7K$7M+0.77%
Q3 201969.0K$6M+0.70%
Q2 201981.5K$6M+0.65%
Q1 201991.5K$9M+1.00%
Q4 2018111.5K$8M+0.93%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of ALNY.